Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > XLO Xilio Therapeutics > Company Executives
XLO Xilio Therapeutics
Pre Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Rene Russo, Pharm.D.Chief Executive Officer and Director5.46M----47female06/16/2022
Mr. Salvatore GiovineChief Financial Officer1.92M----38male07/28/2022
Mr. Paul J. ClancyChairman of the Board509.28K----60male06/16/2022
Dr. Martin H. Huber, M.D.President and Head of Research and Development.3.46M----62male06/16/2022
Dr. Yuan Xu, PhDDirector------54female04/26/2022
Mr. Tomas J. HeymanDirector--------male09/15/2022
Mr. Robert RossDirector--------male06/16/2022
Dr. Michael Ross, PhDIndependent Director305.70K----72male04/26/2022
Ms. Sara BonsteinIndependent Director445.63K----41female04/26/2022
Ms. Christina RossiIndependent Director397.89K----46female04/26/2022
Mr. Daniel CurranIndependent Director------55male04/26/2022
Company Overview More
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
CEO: Russo BCPS, Pharm.D, Pharm.D., Rene
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top